Tag: Oncology

PhoenixMD and WuXi STA Produced Multikilogram Drug Supply for TNBC Treatment

PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices. Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designi...

Biocartis and Kite in Master Development and Commercialization Agreement

Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced that it has entered into a Master Development and Commercialization Agreement with Kite, a G...

ProBioGen and Abcuro in GMP Manufacturing Agreement

ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, announced the closing of a services and license agreement with Abcuro, Inc. Pursuing a new...

Pharmaceutical Companies Reported Strong Q1 Growth of Oncology Drugs Sales

Pharmaceutical companies have reported strong Q1 growth by their oncology drugs, based on earnings reports from Johnson & Johnson, Bristol-Myers Squibb, Bayer, Novartis and AbbVie. A report fro...

Collaboration on Developing First-in-Class Therapeutics for NSCLC

SK Biopharmaceuticals, a pharmaceutical company focused on disorders of central nervous system and cancer, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, announced...

Pharmasyntez—Official Distributor of Segidrin®

The Pharmasyntez Group of Companies became an official distributor of the drug product for palliative therapy Segidrin® (hydrazine sulphate) as a result of signing the Agreement with PJSC Pharmsynthez...

First Dose of Inovio’s dMAb™ Technology

Inovio Pharmaceuticals, Inc. in collaboration with The Wistar Institute and the University of Pennsylvania announced that the first subject was dosed as part of the first-ever human study of Inovio's ...

Anixa, Wistar Institute and Dmitry I. Gabrilovich Focus on MDSC

Anixa Biosciences, Inc., a biotechnology company focused on using the body's immune system to fight cancer, today announced it has extended its collaboration with The Wistar Institute and Dmitry I. Ga...

NICE Recommends Roche’s Breast Cancer Drug for Post-Surgery

NICE has published final draft guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes. This positiv...

3SBio and Verseau Partners in Immuno-Oncology Field

3SBio Inc. and Verseau Therapeutics, Inc. have announced a partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a b...

NeoTX in Clinical Collaboration with AstraZeneca

astrazeneca
NeoTX Therapeutics, Ltd announced that it has entered into a clinical collaboration with AstraZeneca Group Plc global biologics research and development arm, MedImmune, to support Phase 1b/2 studies i...

Grey Wolf to Fund Development of Therapy Increasing Tumour Visibility

Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumours for attack and destruction by the immune system. Grey Wolf Therapeutics, a drug discovery ...

First Drug for Rare Cancer under Priority Review

Daiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become the first systemic drug therapy for rare cancer tenosynovial giant cell tumour (TGCT). The Ja...

GSK and Merck to Develop Cancer Treatment under €3.7bn Deal

GlaxoSmithKline (GSK) and Merck will develop and commercialize novel immunotherapy to treat multiple cancers, under €3.7bn worth deal. The M7824 is an investigational bifunctional fusion protein im...

Developing Treatments for OAC

Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail, unveiling good news that more than half could be targeted by drugs currently already in trials for other...

Roche Plans to Expand Use of its Breast Cancer Drug

Roche has submitted a supplemental biologics license application in the US seeking to expand the use of Kadcyla (trastuzumab emtansine) to include the adjuvant treatment of people with HER2-positive e...